Is It Time to Rethink Standard Anticoagulation? Apixaban vs VKA in HeartMate 3 LVADs
Tania Ahuja, Clinical Assistant Professor, Assistant Director of Clinical Pharmacy and Clinical Pharmacotherapy Specialist, shared a post on X:
”Is it time to re-think anticoagulation for HeartMate3 (HM3) LVADs?
2 RCTs and 3 observational studies including 209 patients: 119 in the apixaban group and 90 in the VKA group demonstrating apixaban just as good as VKA and with less.”
Read the full article here.
Title: Efficacy and safety of apixaban versus vitamin K antagonists in patients with heartmate 3 fully magnetically levitated left ventricular assist device: a comprehensive meta-analysis
Authors: Andrea Tripoli, Miguel A. Samaniego, Norma N. Gamarra-Valverde, Shivraj Paneer Selvam, Edgardo Kaplinsky, Alejandro Barbagelata, Anna Mara Scandroglio, Juliana Giorgi
Stay updated on all science in the field of hematology with Hemostasis Today.
-
Apr 6, 2026, 06:11Priya Prasad: Family Donations Are Not as Safe as We Usually Think
-
Apr 6, 2026, 05:48Isaac Okello: Turning Point from Reliance on Foreign Exports to Self – Reliance Through Local Production of Medical Supplies
-
Apr 6, 2026, 05:34Lena Volland: Scientific Exchange in Bleeding Disorders at the WFH 2026 World Congress
-
Apr 6, 2026, 04:46Ursula Porage Dona: Bringing the Bleeding Disorders Community Together at WFH 2026 with NNHF
-
Apr 6, 2026, 04:17Arun V J: How War Reshaped Blood Transfusion
-
Apr 6, 2026, 03:57Isabella Cieri: How TEG Is Transforming Vascular Surgery Care
-
Apr 5, 2026, 19:00Kausik Ray: Comparing Lipid Management in France vs. Rest of Europe for High Cardiovascular Risk Patients
-
Apr 5, 2026, 18:22Omar Adwan: Systematic Approach to Blood Smear Examination
-
Apr 5, 2026, 18:05Heghine Khachatryan: Rethinking Hemostatic Targets in Pregnancy for von Willebrand Disease